Search

Quercetin and isoquercitrin were reported to have anti-inflammatory effects on typical asthma. Therefore, we investigated quercetin-3-O-glycosides to clarify the potential for treating atypical asthma. The inhibitions of quercetin-3-O-glycosides on PDE1–5 activities and on high-affinity rolipram binding sites were measured. The sensitized guinea-pig trachealis was challenged by ovalbumin (OVA) to induce contractions. Ten female BABL/c mice in each group were sensitized by OVA on days 0 and 14. On day 21, these mice were injected a mixture of 1% OVA and Freund’s complete adjuvant (1:1). Mice were challenged using 1% OVA in saline for 30 min on days 28, 29, and 30 by ultrasonic nebulization. Twenty-four hours after the last nebulization, the blood and bronchoalveolar lavage fluid (BALF) of these mice were collected. Total immunoglobulin (Ig)E or IgG2a level in the serum and cytokines in the both were determined. The number of inflammatory cells was counted using a hemocytometer. Rutin (30 and100 μmol/kg, p.o.) and quercitrin (100 μmol/kg, p.o.) significantly suppressed the increases in the inflammatory cells and cytokines in the BALF of mice. In contrast to rutin, quercitrin significantly increased the IFN-γ level. Both significantly increased the IgG2a level in the serum and suppressed total and OVA-specific IgE levels in the serum and BALF of mice. Rutin, quercitrin, and isoquercitrin did not affect xylazine/ketamine-induced anesthesia. In conclusion, the above results suggest that quercetin-3-O-glycosides have few adverse effects and that rutin and quercitrin, but not isoquercitrin, may have the potential for treating atypical asthma.